^
    Back
    Association details:
    Biomarker:TNFRSF17 amplification
    Cancer:Multiple Myeloma
    Drug:Elrexfio (elranatamab-bcmm) (CD3 agonist, BCMA inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ASCO 2023
    Title:

    Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A.

    Published date:
    05/25/2023
    Excerpt:
    MagnetisMM-3 (NCT04649359) is an open-label, multicenter, non-randomized phase 2 study of elranatamab monotherapy in patients (pts) with multiple myeloma refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug and 1 anti-CD38 antibody....Genome wide copy number analysis showed that TNFRSF17 locus amplification was associated with non-response (p= 0.008).
    DOI:
    10.1200/JCO.2023.41.16_suppl.8045
    Trial ID:
    MagnetisMM-3
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    EHA 2023
    Title:

    GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSEAND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A

    Published date:
    05/11/2023
    Excerpt:
    Genome wide copy number analysis showed that TNFRSF17 locus amplification was associated with non-response(p=0.008)….Features of high-risk disease were also associated with lack of response to elranatamab.
    Trial ID:
    MagnetisMM-3